RT Journal Article
SR Electronic
T1 Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2911
OP 2916
DO 10.21873/anticanres.14268
VO 40
IS 5
A1 AOKI, MASAYA
A1 UEDA, KAZUHIRO
A1 UMEHARA, TADASHI
A1 KAMIMURA, GO
A1 TOKUNAGA, TAKUYA
A1 HARADA-TAKEDA, AYA
A1 MAEDA, KOKI
A1 NAGATA, TOSHIYUKI
A1 YOKOMAKURA, NAOYA
A1 KARIATSUMARI, KOTA
A1 NONAKA, YUTO
A1 IMAMURA, NOBUHIRO
A1 MORIZONO, SHOICHIRO
A1 SATO, MASAMI
YR 2020
UL http://ar.iiarjournals.org/content/40/5/2911.abstract
AB Background: Although oncogene-targeted therapy is a first-line treatment for advanced, unresectable lung adenocarcinoma harboring a target gene mutation, its effect on potentially resectable, locally advanced lung adenocarcinoma remains unclear. Patients and Methods: Ten patients with clinically diagnosed stage III lung adenocarcinoma harboring a target gene mutation were enrolled in the current feasibility study of targeted therapy followed by cytotoxic chemotherapy (platinum and pemetrexed) before radical surgery. Results: Complete resection was accomplished in all nine patients who went on to surgery (one patient refused surgery), and all of these patients recovered without major postoperative complications. Overall, almost all of the patients who underwent surgery remain disease-free after a median follow-up of 22 months since the initial treatment, with only one patient dying of recurrence. Conclusion: Radical surgery after the sequential use of cytostatic and cytotoxic drugs resulted in a favorable short-term outcome.